A PYMNTS Company

US/EU: Baxter pharmaceuticals completes $3.9B buyout

By  |  September 6, 2013

Pharmaceutical giant Baxter reportedly completed is buyout of Switzerland-based healthcare products maker Gambro AB. The deal is valued at $3.9 billion.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Gambro specializes in dialysis products. An offer to acquire the company was made by Baxter in December 2012, and the transaction was approved by the European Commission last July.

    The Commission said Baxter must divest its renal replacement therapy business as a condition to clear the deal.

    Full Content: Kansas City

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.